October 2018
CPHI Madrid

Synchrony progress several exciting projects

October 2018
Product Launch

Synchrony launch in the UK a unique presentation of Labetalol 5mg/ml offering convenience and efficiencies

August 2018
Product Launch

Synchrony launch in the UK the only licensed “ready to use” Magnesium Sulfate 20% w/v

March 2018
New Product Marketing Authorisations

Synchrony received a UK marketing authorisation for Magnesium Sulfate 10%w/v and 20%w/v. A number of other Synchrony product developments are advancing through the regulatory approval process.

January 2018
Wave 11 tender award

Synchrony are pleased to announce the award to supply three hospital products in the latest NHS tender. This further strengthens our position as a partner of choice in the UK market.

October 2017
CPHI Frankfurt

Synchrony met with several development and commercial partners. An agreement to develop two further speciality products signed. To add to our commercial network a further two out-licensing deals were concluded.

May 2017
CPhI China, 20th – 22nd June 2017

Synchrony Pharma will attend CPhI China to meet with existing and potential new partners to further our development pipeline. Please contact us to arrange any meetings to discuss co-developments, contract development and licensing deals.

April 2017
Wave 10c tender award

We are pleased to announce that Synchrony has been awarded significant contracts across several products in the latest NHS tender. This continues our strong performance in NHS tenders and further strengthens our UK business.

November 2016
Niche generic portfolio advances

Synchrony has received Day 100 questions from the MHRA on two MA applications for our Niche Generic portfolio. A comprehensive response is being prepared to move these products towards commercialisation.

November 2016
NHS Wales

Synchrony has been awarded a contract by NHS Wales, further expanding the number of hospitals we support in the UK.

October 2016
New injectable product development deal

Synchrony has signed an agreement for the development of two generic injectable products. These products have great commercial potential in both the UK and globally. UK MHRA MA applications are planned for the second half of 2017.

September 2016
CPhI Barcelona, 4th – 6th October 2016

Synchrony will be attending CPhI in Barcelona from 4th to 6th October 2016. Please contact us to arrange any meetings.

March 2016
Submission of niche generic to MHRA

Synchrony has submitted its application for a Marketing Authorisation of a niche injectable formulation further broadening its portfolio and renewing its commitment to novel and niche product developments. Further news to appear here.

February 2016
Pemetrexed 500mg EU DCP approved

Synchrony Pharma’s development of Pemetrexed has gained EU approval in several markets via a DCP procedure. This is further validation of Synchrony Pharma’s robust approach to product development. Commercialisation planning for early entry markets in underway.

February 2016
euroPLX 60

Synchrony will be attending euroPLX 60 in Barcelona from 7th to 8th March 2016.

November 2015
Two in licensing deals announced

Following CPhI Madrid in October Synchrony has finalised two further in-license deals for injectable products for the UK. Further in-license and development projects are in the pipeline.

September 2015
CPhI Madrid

Synchrony will be attending CPhI in Madrid from 13th to 15th October 2015.

July 2015
First to market on Bortezomib

Following the approval of Synchrony’s Bortezomib dossier earlier in the year our partner network has successfully launched as first to market Czech Republic and Slovakia.

May 2015
euroPLX 58

Synchrony will be attending euroPLX 58 in Munich from 1st to 2nd June 2015.

April 2015
Synchrony awarded contract in latest NHS tender

The Commercial Medicines Unit have awarded Synchrony supply contracts in the latest generic tender wave. The contract will run until 2017 and continues Synchrony’s successful history in UK tenders.

March 2015
Bortezomib 3.5mg EU DCP approved

Synchrony Pharma’s development of Bortezomib has gained EU approval in several markets via a DCP procedure. The smooth management of the procedure and this positive outcome now position Synchrony’s partners to be amongst the first to market in certain countries.